Ruthenium-106 ocular surface brachytherapy for incompletely excised conjunctival melanoma and squamous cell…

Cohort studyJournal of contemporary brachytherapy· Jun 2026

Ruthenium-106 ocular surface brachytherapy for incompletely excised conjunctival melanoma and squamous cell carcinoma.

Efstathios T Detorakis, Georgia Solomou, Maria Detoraki, Kostas Perisinakis

Read paper

Ocular OncologyCohort studyTreatmentQ3IF 1.4

Ruthenium-106 brachytherapy was associated with a 75% local tumor control rate for incompletely excised conjunctival malignancies.

Ruthenium-106 ocular surface brachytherapy for incompletely excised conjunctival melanoma and squamous cell carcinoma.

Efstathios T Detorakis … Kostas Perisinakis

Journal of contemporary brachytherapy · Jun 2026

Purpose

To examine the efficacy and safety of ruthenium-106 ( 106 Ru) ocular surface brachytherapy for incompletely excised conjunctival melanoma (conjunctival melanoma) and conjunctival squamous cell carcinoma (conjunctival squamous cell carcinoma) patients, with no adjunctive treatments applied to the primary tumor beds treated with 106 Ru brachytherapy.

Methods

A retrospective analysis of a consecutive cohort of eight patients (four with conjunctival melanoma and four with conjunctival squamous cell carcinoma), treated at the Department of Ophthalmology of the University Hospital of Heraklion, was performed.

Results

75%

75% of patients had their conjunctival melanoma or squamous cell carcinoma controlled locally.

More results

In two patients (one conjunctival melanoma and one conjunctival squamous cell carcinoma), orbital exenteration was required due to orbital invasion.

Both cases involved neglected and extensive lesions, suggesting possible pre-existing microscopic deeper infiltration.

No radiation-related ocular surface toxicity was observed.

“

Conclusion · 1 of 2

In line with previous reports, these findings highlight the role of ocular surface brachytherapy in the management of incompletely excised conjunctival malignancies.

Conclusion · 2 of 2

Ruthenium-106 surface brachytherapy may represent an effective sole adjunctive treatment option for selected cases of conjunctival melanoma and conjunctival squamous cell carcinoma, even when using plaques designed for intra-ocular applications, such as CCB (BEBIG) plaque.

Ruthenium-106 ocular surface brachytherapy for incompletely excised conjunctival melanoma and squamous cell carcinoma.

Ruthenium-106 ocular surface brachytherapy for incompletely excised conjunctival melanoma and squamous cell carcinoma.

Related papers